Epizyme, Inc. (NASDAQ:EPZM) has reported positive interim data from an ongoing Phase II trial of tazemetostat as a monotherapy to treat patients with relapsed or refractory follicular lymphoma (FL). The data shows that the company’s lead candidate tazemetostat demonstrated meaningful clinical activity and was generally well tolerated in patients with EZH2 activating mutations, as well as with wild-type EZH2. Epizyme chief medical officer Dr Shefali Agarwal said: “FL is an indolent, incurable disease, for which patients are in need of new effective and tolerable treatment options.
Epizyme, Inc. (NASDAQ:EPZM), a Healthcare sector firm, traded 1.73 Million shares in last trading session with closing price of $15.12 per share. Company return on investment (ROI) is -55.00%. Stock value has moved between $5.14 – 15.12 in last one year. Analyst’s mean target price for Epizyme, Inc. (NASDAQ:EPZM) is $18.56 while analysts mean recommendation is 1.60. EPZM EPS growth this year is 21.30%.
On last trading day, Prevail Therapeutics Inc. (NASDAQ:PRVL) shares closed at $15.71 per share. PRVL market capitalization is 534.09. Its year to date (YTD) performance is 15.51%.
In last session CEL-SCI Corporation (NYSE:CVM) traded 1.47 Million shares and was closed at $8.67. Analyst’s mean target price for CVM is $14.00. Company is 2.36% away from its 52 week high and is moving 961.85% ahead of its 52 week low. CVM return on assets is -102.60%. CEL-SCI Corporation (NYSE:CVM) quarterly performance is 187.09% while its price to sale ratio is 548.64.
Boot Barn Holdings, Inc. (NYSE:BOOT), a Services sector firm, traded 1.18 Million shares on last trading day with closing price of $35.08 per share. Company gross margin stands at 32.40% whereas its return on investment (ROI) is 12.30%. Stock value has moved between $14.99 – 34.73 in last one year. Analyst’s mean target price for Boot Barn Holdings, Inc. (NYSE:BOOT) is $34.00 while analysts mean recommendation is 1.80. BOOT EPS growth this year is 70.40%.